Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | PRKX | P51817 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348964 | 0.79 | DPP4 (0.42) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL20975555 | 0.79 | MAPT (0.43) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL4607622 | 0.79 | LMNA (0.40) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL14722640 | 0.79 | LMNA (0.40) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL3045187 | 0.79 | MEN1 (0.44) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL3611391 | 0.79 | KDM4E (0.44) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL18663582 | 0.79 | MAPT (0.43) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL17307154 | 0.76 | DPP4 (0.40) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL20472000 | 0.75 | BRD4 (0.47) | DPP4DPP8LMNAMEN1KMT2A | |
| SCHEMBL17308779 | 0.75 | DPP4 (0.49) | DPP4DPP8LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| CN-106414448-B | It can be used as the new compound of S100- inhibitor | 活跃生物技术有限公司 | 2019-04-19 | — | — | CN | disclosed |
| WO-2018147626-A1 | NOVEL HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-08-16 | — | — | WO | disclosed |
| CN-106414448-A | Novel compounds useful as s100-inhibitors | 活跃生物技术有限公司 | 2017-02-15 | — | — | CN | disclosed |
| WO-2016040764-A1 | CARBONYL LINKED BICYCLIC HETEROARYL N-BENZIMIDAZOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-8211590-B2 | Proton conducting material, and electrode and fuel cell using the same | PANASONIC CORPORATION (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090017356-A1 | PROTON CONDUCTING MATERIAL, AND ELECTRODE AND FUEL CELL USING THE SAME | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-3988155-A | CYANINE SENSITIZING DYES | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-26 | — | — | US | disclosed |
| US-3985563-A | Silver halide photographic emulsion | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | DPP4 1264/4885DPP8 1055/4885LMNA 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.